TRVI - Trevi Therapeutics: A Promising Pruritus Player In 2020
Today, we will be studying why Trevi Therapeutics (TRVI) is an attractive investment for 2020.
Company overview
Trevi Therapeutics is a clinical-stage company focused on the development of nalbuphine ER to treat multiple serious and chronic neurologically mediated conditions. Nalbuphine ER is a unique oral formulation of small molecule drug nalbuphine. The company is studying Nalbuphine ER in Phase 2/3 trial in Prurigo nodularis, in Phase 2 trial for Uremic pruritus, and in phase 1 trial for pruritus associated with chronic liver disease. Besides chronic pruritic conditions, the company is also studying